RayKnowChina Research Map
Shortlist

RecruitingLung cancerPancreatic cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

An open trial on lung cancer and pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 24 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 24

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Inner Mongolia Medical University内蒙古医科大学附属医院HohhotHospital page
  2. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  3. Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
  4. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  5. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  6. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  7. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  8. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  9. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  10. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  11. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  12. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  13. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  14. Study siteLinYi Cancer HospitalLinyiHospital page
  15. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  16. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  17. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  18. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  19. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  20. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  21. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  22. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  23. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  24. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05288205, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC;

    Inclusion criterion 2

  3. Eastern Cooperative Oncology Group(ECOG) performance status 0-1;

    Inclusion criterion 5

  4. HIV, hepatitis B virus(HBV), or hepatitis C virus(HCV) positive;

    Exclusion criterion 4

  5. Pregnant or lactating women

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05288205, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • A written informed consent should be signed by a subject or his/her legal representative before any study-related procedures are performed;
  • Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC;
  • Expected survival ≥ 3 months;
  • Subjects must have at least one measurable lesion as defined by RECIST v1.1. If no measurable lesion untreated with radiation is selected as the target lesion, a lesion treated with radiation ≥ 4 weeks before the first dose and with progression confirmed by radiography may be selected as the target lesion;
  • Eastern Cooperative Oncology Group(ECOG) performance status 0-1;
  • The organ functions of subjects meet the criteria for the following laboratory parameters at screening;
  • Subjects must be able to swallow oral medications without gastrointestinal abnormalities that significantly affect drug absorption

Exclusion Criteria:

  • Patients with previous (≤ 3 years) or current tumors of other pathological types, except for cured cervical carcinoma in situ, ductal carcinoma in situ of the breast, prostatic intraepithelial neoplasia, superficial non-invasive bladder cancer, stage I skin cancer (except melanoma); subjects without recurrence or metastasis for > 3 years after treatment, without current evidence of tumor, and without significant risk of recurrence of previous malignant diseases in the opinion of the study doctor may also be enrolled;
  • Serious allergy to the investigational drug or excipients (such as microcrystalline cellulose, etc.);
  • Patients with previous (≤ 6 months before the initiation of treatment) or current severe autoimmune diseases (including adverse reactions caused by previous anti- tumor immunotherapies), or autoimmune diseases requiring long-term systemic hormone therapy at immunosuppressive dose levels (prednisone > 10 mg/day or equivalent drugs);
  • HIV, hepatitis B virus(HBV), or hepatitis C virus(HCV) positive;
  • Previous (≤ 6 months prior to the first dose) or current evidence of the following diseases: acute myocardial infarction, unstable angina and cerebrovascular accident;
  • Subjects who have impaired cardiac functions or clinically significant cardiac diseases;
  • Pregnant or lactating women

Quoted from ClinicalTrials.gov, NCT05288205, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05288205, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05288205